Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Dermatol. 2008 Jun;47(6):622-5. doi: 10.1111/j.1365-4632.2008.03534.x.

Bone mineral density and bone turnover markers in patients receiving a single course of isotretinoin for nodulocystic acne.

Author information

  • 1Department of Dermatology, Faculty of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey. nilgunstekin@yahoo.com

Abstract

BACKGROUND:

High-dose isotretinoin has been reported to have adverse effects on bone mineral density (BMD); however, studies evaluating changes in BMD with isotretinoin therapy at different dosages and with varying treatment durations have produced conflicting results.

OBJECTIVE:

To investigate the effect of a standard, single course of isotretinoin therapy on BMD and bone turnover markers in patients with nodulocystic acne.

METHODS:

Thirty-six patients (15 male, 21 female) with severe, recalcitrant, nodulocystic acne and 36 healthy controls (16 male, 20 female) were enrolled in the study. Patients received isotretinoin treatment for 4-6 months until a cumulative dose of 120 mg/kg had been achieved. BMD in the lumbar spine and femur was measured at baseline and at the end of therapy by dual-energy X-ray absorptiometry. Serum calcium, phosphate, parathormone, total alkaline phosphatase, osteocalcin, free deoxypyridinoline, and urinary calcium were also measured before and at the end of treatment.

RESULTS:

No significant differences were found in lumbar spine and femoral BMD between the patient and control groups at the beginning of the study (P > 0.05), and no statistically significant difference was observed between the BMD values in patients at the beginning vs. the end of treatment (P > 0.05). No statistically significant difference in bone turnover markers was found between patients and controls at the beginning of the study (P > 0.05), and no statistically significant changes in bone turnover markers were observed in patients at the beginning vs. the end of treatment (P > 0.05).

CONCLUSION:

A single course of isotretinoin therapy has no clinically significant effect on bone metabolism.

PMID:
18477161
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk